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Abstract 
Sphingolipid storage diseases are a group of disorders, caused by defects in 
lysosomal hydrolytic processes or lipid transport that lead to the accumulation of lipids in 
the endosomal-lysosomal system. Among this group are the Niemann-Pick disorders. The 
Niemann-Pick type C (NPC) is characterized by a progressive neurodegenerative 
phenotype and is caused by mutations in NPC1 (95% of the cases) or NPC2 (5% of the 
cases). Both proteins seem to regulate intracellular lipid transport between lysosomes and 
endosomes. It has been suggested that alterations in this transport compromises 
mitochondrial activity.  
The yeast Saccharomyces cerevisiae Ncr1p is an orthologue of human NPC1 
protein. It seems to be involved in ergosterol trafficking and can functionally complement 
the loss of human NPC1, suppressing lipid trafficking defects in NPC cells. Yeast cells 
deleted for NCR1 have been used as a eukaryotic model system to characterize 
conserved cellular mechanisms associated with NPC1 disease.  
This work aims to uncover the role of Ncr1p in oxidative stress resistance and 
mitochondrial function and to characterize changes in cell signalling pathways associated 
with ǻncr1 phenotype. Wild type and ǻncr1 mutant cells were treated with hydrogen 
peroxide or menadione, a superoxide generating drug, and cellular viability was 
determined and correlated with oxidative stress markers, namely protein carbonylation, 
levels of reactive oxygen species and lipid peroxidation. The results show that ǻncr1 cells 
exhibited a significant decrease in hydrogen peroxide resistance, compared to the 
observed in wild type cells, associated with an increase of oxidative stress markers. 
However, menadione resistance was not affected in the mutant strain. 
Moreover, Ncr1p deficiency was associated with loss of mitochondrial function, as 
shown by the incapacity of this mutant to grow on glycerol medium, a non-fermentable 
carbon source. Mitochondrial function is important for oxidative stress resistance and is 
regulated by protein kinases and phosphatases, such as Tor1p, Sit4p and Sch9p. Tor1p is 
the phosphatidylinositol-related protein kinase subunit of the rapamycin-sensitive TORC1 
complex that controls cell growth in response to nutrient availability and cellular stresses. 
Sit4p is a serine-threonine ceramide-activated protein phosphatase related to type 2A 
family of protein phosphatases (PP2A) that are involved in cell cycle regulation. Sch9p is 
a serine-threonine kinase with possible homology to mammalian ribosomal S6 kinase 
(S6K) or Protein Kinase B (PKB/AKT) that is activated by TORC1 or phytosphingosine 
through Pkh1/2p pathway and is involved in the regulation of glucose metabolism. 
Notably, the hydrogen peroxide sensitivity and the growth defect on glycerol displayed by 
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ǻncr1 cells were suppressed by deletion of SIT4 and SCH9 but not by TOR1. The 
oxidative stress resistance of ǻncr1ǻsit4 and ǻncr1ǻsch9 double mutants was associated 
with lower levels of reactive oxygen species.  
These results suggest that Ncr1p regulate cellular processes important for 
mitochondrial function and hydrogen peroxide resistance through modulation if Sit4p and 
Sch9p signalling pathways.  
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Resumo 
As doenças de armazenamento de esfingolípidos constituem um grupo de 
doenças causadas por defeitos em processos lisossomais ou transporte lipídico, 
originando a acumulação de lípidos no sistema endossomal-lisossomal. Entre este grupo 
encontra-se a doença de Niemann-Pick. A doença de Niemann-Pick do tipo C (NPC) é 
caracterizada por um fenótipo neurodegenerativo progressivo e é causada por mutações 
em NPC1 (95 % dos casos) ou NPC2 (5 % dos casos). Estas proteínas parecem estar 
envolvidas na regulação do transporte lipídico intracelular entre lisossomas e 
endossomas.  
Tem sido sugerido que alterações neste transporte comprometem a actividade da 
mitocôndria. A levedura Saccharomyces cerevisiae possui uma proteína ortóloga à NPC1 
humana que se designa por Ncr1p. Esta proteína parece estar envolvida no transporte de 
ergosterol em levedura e consegue complementar funcionalmente a perda de NPC1 
humana, suprimindo os defeitos no transporte lipídico em células de NPC. As leveduras 
com deleção do gene NCR1 tem sido usadas para caracterizarem mecanismos celulares 
conservados associados a doença de NPC1. 
Este trabalho tem como objectivo estudar o papel da proteína Ncr1p na 
resistência ao stress oxidativo e disfunções mitocondriais, bem como, caracterizar 
DOWHUDo}HVHPYLDVGHVLQDOL]DomRDVVRFLDGDVFRPRIHQyWLSRGDVFpOXODVǻncr1. A estirpe 
selvagem e respectivos mutantes ǻncr1 foram tratadas com peróxido de hidrogénio ou 
menadiona (utilizada para induzir formação de anião superóxido) e a viabilidade celular 
foi correlacionado com marcadores de stress oxidativo, tais como, níveis de espécies 
reactivas de oxigénio intracelulares, peroxidação lipídica e carbonilação de proteínas. Os 
resultados demonstram uma diminuição significativa da resistência ao peróxido de 
hidrogénio por parte do mutante ǻncr1 comparado com o observado na estirpe selvagem, 
associado com o aumento dos marcadores de stress oxidativo. Contudo, a resistência a 
menadiona não foi afectada na estirpe mutante. 
 Além disso, a deficiência em Ncr1p foi relacionada com perda da função 
mitocondrial, como demonstrado pela incapacidade do mutante crescer em meio com 
glicerol (uma fonte de carbono não fermentável). A função mitocondrial é importante para 
a resistência ao stress oxidativo e é regulada por proteínas cinases e fosfatases tais 
como Tor1p, Sit4p e Sch9p. Tor1p é uma proteína cinase, subunidade do complexo 
TORC1 (sensível a rapamicina) que controla o crescimento celular em resposta a 
nutrientes e stress celular. Sit4p é uma serina- treonina fosfatase activada por ceramida e 
relacionada com a família das proteínas fosfatases do tipo 2A (PP2A) que esta envolvida 
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na regulação do ciclo celular. Sch9p é uma serina-treonina cinase que tem possível 
homologia com a cinase ribossomal S6 (S6K) ou a proteína cinase B (PKB/AKT) dos 
mamíferos. Esta proteína é directamente activada pelo TORC1 ou por fitoesfingosina 
através da via do Pkh1/2p e está envolvida na regulação do metabolismo da glucose. 
Curiosamente a deleção dos genes SIT4 e SCH9 suprimiram a sensibilidade ao peróxido 
de hidrogénio bem como os defeitos no crescimento em glicerol exibidos pelas células 
ǻncr1, mas o mesmo não se verificou com a deleção do TOR1. A resistência ao stress 
oxidativo dos duplos mutantes ǻncr1ǻsit4 e ǻncr1ǻsch9.foi associada com níveis 
diminuídos de espécies reactivas de oxigénio. 
Estes resultados sugerem que a proteína Ncr1p regula processos celulares 
importantes para a função mitocondrial e resistência ao peróxido de hidrogénio através 
da modulação das vias de sinalização do Sit4p e Sch9p. 
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1. Niemann-Pick disease 
 
Sphingolipid-storage diseases are a group of genetic disorders triggered by 
deficiencies in lysosomal hydrolytic activities or lipid transport that results in the 
accumulation of lipids (e.g., cholesterol) in the endossomal-lysosomal network [1]. Among 
this group is Niemann-Pick. Albert Niemann and Ludwig Pick were the pioneers 
GHVFULELQJ WKLV GLVHDVH LQ  7KH WHUP ³1LHPDQQ-Pick diseDVH´ KDV EHHQ XVHG WR
designate a heterogeneous group of autosomal recessive lysosomal disorders, with 
common types of hepatosplenomegaly and sphingomyelin storage in reticuloendothelial 
and parenchymal tissue, with or without neurological involvement [2]. In 1958, Crocker 
and Farber demonstrated that there was a broad variability in age of onset, clinical 
expression and in the level of sphingomyelin storage in tissues, which led to a 
classification of this disorder into four subgroups: A to D [3]. Patients with type A exhibited 
a severe neurovisceral disease, while type B had a chronic course with visceral 
contribution only. The accumulation of sphingomyelin was found in those patients [3], and 
later work demonstrated a loss of efficiency in acidic sphingomyelinase allowing the 
classification of type A and B as sphingomyelin storage disorders [4]. These results were 
not verified in patients with Niemann-Pick type C and D, which have a sub-acute nervous 
system involvement, with moderate/slower course and a mild visceral storage. Type D 
patients were individualized essentially on their homogenous Nova Scotia Acadian origin 
(allelic to type C). Later work led to a reclassification of type C as a cellular lipid trafficking 
disorder [5]. 
 
2. Niemann-Pick Type C (NPC) 
 
Niemann-Pick type C (NPC) designates disorders characterized by unique 
abnormalities of intracellular transport of endocytosed cholesterol with accumulation of 
unesterified cholesterol in lysosomes, late endosomes and Golgi complex [2,6]. Besides 
cholesterol sequestration, NPC cells accumulate other lipids in particular sphingomyelin 
(SM), glycosphingolipids (GSLs) and sphingosine [7±11]. NPC is related to a progressive 
neurodegenerative phenotype and in most cases is fatal [12]. 
Advances in the knowledge of the disease led to the description of two genetic 
complementation groups and the subsequent characterization of the two genes: NPC1 
and NPC2. They are represented in different proportions in the population ± NPC1 is 
involved in 95% of the cases [12], while NPC2 is related to rare cases [2]. NPC is caused 
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by loss-of-function point mutations in either NPC1 or NPC2 proteins, which mediate 
proper intracellular lipid transport through pathways that remain unclear [1]. 
 
 
2.1. Epidemiology 
 
The prevalence of NPC is difficult to estimate, not only because of the insufficient 
clinical awareness and difficult diagnosis but also to a relative difficulty of biochemical 
testing. The prevalence in Western Europe (France, UK, and Germany) has been 
estimated to be around 0.66 to 0.83 births per 100.000. In Australia, Netherland and 
Portugal the prevalence is 0.45, 0.37 and 2.2 per 100.000, respectively. The low 
prevalence in some countries may be explained by a lack of diagnosis in the years of birth 
and the fact that the clinical spectrum was only recognized in the early 1990s [2,13,14]. 
 
 
2.2. Clinical description and diagnosis  
 
NPC has an extremely heterogeneous clinical presentation characterized by a 
wide variety of symptoms that are not specific to the disease and with an age of onset 
fluctuating from perinatal period until adult age [2,15]. The lifespan of the patients varies 
between a few days until over 60 years of age [16,17], and there is no exact correlation 
between disease-causing mutations and severity of clinical phenotype [18]. 
Classically, NPC is a neurovisceral condition. This disease affects internal organs 
(liver and spleen) and the first symptoms usually described are hepatosplenomegaly (that 
seems to be variable and decrease with time) or obstructive jaundice. Except for the 
perinatal period, the systemic disease is usually not very severe and well tolerated. Apart 
from a small percentage of patients that die at birth, or in the first 6 months of life, and 
exceptional adult cases, all patients develop a progressive and fatal neurological disease 
[1,2].  
This disease can be classified into four major groups according to the onset of 
neurological symptoms: early infantile, late infantile, juvenile, and adult forms [18]. 
However, the classic form of NPC, which accounts for 60-70 % of the cases, appears 
between the ages of 3 and 15 years [1].The age at arrival of neurological symptoms has a 
major influence on disease progression. If neurological symptoms arise early in life, the 
rate of deterioration is generally faster and premature death occurs sooner [15]. The 
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neurological symptoms can be very diverse, according to the age of onset of the disease 
and are resumed in the Figure 1.1.    
 
 
Figure 1.1- Niemann-Pick disease type C as a neurovisceral disease. Adapted from [2] 
 
 
The heterogeneity of the clinical manifestations of NPC disease is not totally 
detected when it comes to the biochemical level of the disease. The majority of cases 
present prominent accumulations of unesterified cholesterol, sphingolipids and complex 
gangliosides in late endosomes and lysosomes, but a subset of patients with specific 
mutations reveals less lipid storage [19]. The evolution of NPC in the peripheral tissues is 
characterised by an enlargement of the liver and the spleen that results from the presence 
of lipid-laden macrophages. Kupffer cells (resident macrophages) in liver and splenic 
macrophages exhibit a clear cytoplasmic vacuolization that results from the accumulation 
of cholesterol, phospholipids and glycolipids [1]. Impairment of lipid trafficking also has 
severe consequences in the central nervous system (CNS), leading to neuron loss 
throughout the brain [20]. Similarly to other neurodegenerative diseases, such as 
Alzheimer disease, NPC cells accumulate intracellular aggregates of microtubule-binding 
protein tau [21]. 
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Because NPC is a very heterogeneous disease, the correct diagnosis is often very 
difficult to achieve. Even after multiple clinical screening tests to distinguish NPC from 
other neurological diseases, the validation of the diagnosis requires also biochemical and 
molecular-genetic laboratory testing. The key laboratory diagnostic test for NPC is filipin 
staining of cultured skin fibroblasts from patients, to detect the accumulation of free 
cholesterol in lysosomes, and a biochemical approach, to monitor defective cholesterol 
esterification in low density lipoprotein (LDL)-challenged cells [22]. Finally, a molecular 
genetic test for NPC1 and NPC2 is essential to a prenatal diagnosis, and to confirm 
diagnosis in patients with a different biochemical phenotype [15,22]. Although there are 
therapies for some of the clinical manifestations, currently there are no effective 
treatments available to patients with this disorder [1]. 
 
 
2.3. NPC1 and NPC2 
 
NPC disease is genetically heterogeneous, and it is possible to distinguish two 
complementation groups: NPC1 and NPC2. NPC1, the major group for this disease, was 
mapped to the proximal long arm of chromosome 18, and mutations in NPC1 were found 
in approximately 95 % of the patients with NPC [23]. NPC2 was mapped to the long arm 
of chromosome 14 and mutations in NPC2 were found in a minor group of patients (5%) 
[24]. 
The NPC1 gene is localized in chromosome 18q11-q12 and translates a 1278 
amino acid membrane protein with 13 transmembrane domains, which is localised in late 
endosomes and interact with lysosomes and the trans-Golgi network [25,26]. This protein 
has numerous domains that are preserved among species. The sterol sensing domain 
(SSD) is localized in the region between amino acids 615 and 797, and display high 
homology to SSD of other integral membrane proteins that act in response to endoplasmic 
reticulum (ER) cholesterol (HMG-CoA reductase) [27].The NPC1 domain (amino acids 55-
165) is localized in the N-terminal loop and contains a leucine zipper motif (amino acids 
73-94). Also, there is a large cysteine-rich loop found between amino acids 855-1098, 
which contains a ring-finger motif and is a likely site for protein-protein interactions (Figure 
1.2) [28]. 
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Figure 1.2- Topology of NPC1. LE/Lys, late endosomes/lysosomes. TM, 
transmembrane region. Adapted from [11]. 
 
 
 
The number of mutations that cause NPC1 disease is approximately 300, with a 
large majority of missense mutations, and more than 60 polymorphisms have been 
described in NPC1 gene [2]. The missense mutations are spread throughout the NPC1 
gene and influence the functional domains, except the leucine zipper motif. More than 
one-third of the mutations are localized in the cysteine-rich loop, and there is a hot spot 
that contain three of the most frequent mutations, localised between amino acids 927 and 
958 [28]. The most frequent mutation is in the allele encoding p.I1061T, is related with 
prominent  disturbs in fibroblasts  cholesterol trafficking of patients and with a juvenile 
neurological onset of NPC [29]. There are few studies on genotype-phenotype relations 
but, the NPC1 patients generally present a good correlation between nonsense or 
frameshift mutations and the most severe neurological course. The SSD (along with 
cysteine-rich luminal loop) also have mutations that highlighted the significant function of 
both domains. Homozygous mutations in SSD seem to be very harmful, corresponding to 
a lack of mature NPC1 protein and to a very severe phenotype at both clinical and 
biochemical levels [30]. The distribution of the mutations in the NPC1 protein is illustrated 
in the Figure 1.3. 
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Figure 1.3 - Topology of NPC1 mutations. Adapted from [28]. 
 
 
NPC2 encodes a small (132 amino acids) and soluble lysosomal protein. This 
proteins is transported to the lysosome via the mannose-6-phosphate receptor and binds 
to cholesterol with high affinity [31]. Mutations in this protein are associated with very 
severe clinical phenotypes [19,32]. The mature form of NPC2 is a glycoprotein expressed 
abundantly in several tissues [24]. Studies show that NPC2 has high affinity to cholesterol 
and identified a hydrophobic cholesterol-binding pocket [33]. There are few cases of 
NPC2 disease, but all of them show remarkable abnormalities of cellular cholesterol 
processing. It was suggested that NPC1 could be a regulator of NPC2 transport, but it 
was not confirmed. With the increase of NPC2 cases, it is clear that it has also high 
heterogeneity as observed for NPC1 [28]. 
The exact functions of NPC1 and NPC2 proteins have not yet been fully 
elucidated. Regarding the function of NPC1, one study based on its homology with 
prokaryotic permeases of the resistance-nodulation-division (RND) family showed that 
NPC1 may function as a transmembrane molecular pump, which acts as a permease 
transporting fatty acids across cellular membrane in Escherichia coli [27]. Despite some 
ambiguous results, some experimental data suggest that NPC1 plays a role in regulation 
or mediation of retrograde transport of lysosomal cargo in the late endossomal-lysosomal 
pathway [26]. The majority of cell biological studies regarding NPC pathology are referent 
to cells defective only in NPC1. In fact, NPC2 patients are rare and the models of study 
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are scarce. NPC1 has several models of work, such as tissue samples from affected 
patients, cells from NPC1-/- mice [34] or several cell lines in which NPC1 has been 
mutated [1]. 
There are strong evidences that the NPC1 and NPC2 proteins function in the 
same pathway, because mutations in both genes induce a similar phenotype.  
Furthermore, genetic studies reveal that NPC2 alone is not sufficient for cholesterol 
egress from lysosomes, and hence it requires NPC1 [35]. Based on this knowledge, some 
models were described to try to explain how these proteins cooperate. One example 
proposed by Kown and associates is illustrated in figure 1.4. In this model, cholesterol 
released within the lysosome binds to NPC2 with its hydroxyl group exposed. Then, 
cholesterol is transfered to the N-terminal domain of NPC1, reversing its orientation, so 
that the hydrophobic side chain could lead the way into the membrane and/or the 
glycocalix [35]. 
 
 
 
Figure 1.4- Proposed pathway for sequential transfer of cholesterol from LDL to 
NPC2, NPC1 and membranes. Adapted from [35]. 
 
 
 
This model is so far only a theory, because the exact functions of the NPC1 and 
NPC2 proteins are still unclear, which greatly complicates the understanding of the 
pathophysiology of this disease. 
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In contrast to several other lipidosis that result from defects in enzyme activity, 
NPC seems to represent a primary transport defect. The failure of cholesterol 
homeostasis in NPC cells is known but whether the cholesterol transport defect is the 
main problem or potentially a consequence of some other malfunction remains unclear [6]. 
 
 
2.4. Cholesterol transport defects in NPC 
 
Several studies demonstrate a disruption in intracellular transport of endocytosed 
cholesterol in cultured skin fibroblasts from NPC patients. After endocytosis, LDL are 
transported to late endosomes/lysosomes, where they are hydrolysed, and free 
cholesterol can be released. The cholesterol in normal cells is quickly transported out of 
endosomes and delivered to the plasma membrane, ER and Golgi complex. In NPC 
disease the cholesterol is not able to exit the endocytic pathway and is accumulated within 
lysosomes (Figure 1.5).   
 
 
Figure 1.5 - Lipid trafficking defects in NPC. Adapted from [1]. 
 
This defect in trafficking constitutes the hallmark of the disease. Owed to this storage, 
there are a retarding in the LDL cholesterol-mediated homeostatic responses (more 
specifically cholesteryl ester formation). Normal responses can be induced by membrane 
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permeable oxysterol and by mevalonate, showing that the ability of the cell to respond is 
maintained [2]. 
This distinctive deficiency in processing and utilization of cholesterol by the cells 
plays a key role in the pathogenesis of the NPC disease. It may explain a more general 
dysfunction of intracellular metabolism of lipids, at least for extraneuronal organs [36]. 
Accumulation of cholesterol might also modulate endosome proteins such as Rab9 and 
mannose-6-phosphate receptors, two important proteins for the normal function of the 
endossomal/lysosomal system. There are some evidences that accumulation of 
cholesterol in late endosomes can impair vesicular trafficking pathways [37]. 
The pathogenesis of neuronal dysfunctions seems to be far more complex. The 
brain does not take up serum lipoproteins for cholesterol supply. Practically all cholesterol 
in the central nervous system is synthesized de novo [6]. Some studies demonstrated that 
cholesterol accumulated in cell bodies but its levels decreased in distal axons leading to 
an imbalance in the distribution [38]. There are also some evidences that cholesterol 
synthesized de novo may contribute significantly to the cholesterol accumulation in 
various cells types including glia cells [39]. 
 
 
 
2.5.  Lipid storage  
 
Although cholesterol has a major role in NPC cells anomaly, this lipid is not the 
only one involved in the disease. Indeed, other lipids such as sphingolipids accumulate in 
cells with NPC phenotype [11]. 
Sphingolipids are important structural and regulatory components of cell 
membranes. They are considered as bioactive lipids since the variation of their levels 
results in modifications in cellular functions [40]. In the last decades, sphingolipids have 
emerged as important players in different cellular processes, such as cellular growth, 
aging, cell death, nutrient transport, mitochondrial function, oxidative stress, angiogenesis 
and inflammation [41]. Sphingolipids have an amphipathic nature and are composed by a 
long chain sphingoid base (LCB), a fatty acid and a polar head group. The nature of LCBs 
and fatty acids vary between organisms. Mammalian sphingolipids differ in chain length, 
degree of saturation and hydroxylation whereas yeast has more strict unsaturated 26 
carbons long fatty acids [42].  
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The major sphingolipids accumulated in NPC cells are glycosphingolipids, 
sphingomyelin and sphingosine [7,8,11]. The heterogeneity of storage material in NPC is 
well reflected in the brain, where the major storage lipids are GSL. There are many 
possible reasons for this event, among which are altered vesicular transport and impaired 
catabolism [11]. The question is if GSL contribute directly to the disease. Gangliosides 
(GM2 and GM3) are the more relevant GSL stored in other lysosomal storage disease 
LSD, being responsible for the observed severe neuropathology. To test if the 
gangliosides accumulation has a major role in the neuronal dysfunction of NPC disease, 
NPC1 mouse was crossed with mice lacking the polypeptide N-acetylgalactosaminyl-
transferase (GalNac transferase), the enzyme responsible for the synthesis of GM1, GM2 
and more complex gangliosides. Although the descendent mice are unable to synthesize 
complex gangliosides, the phenotype of the disease remain the same, suggesting that 
gangliosides per se are not responsible for the neuronal dysfunctions in this disease [43]. 
 Sphingomyelin is elevated in peripheral tissues. Storage of SM together with the 
reduced activity of acid sphingomyelinase gave the name originally to the disease. There 
is a relationship between SM and cholesterol that is shown by the effects of adding 
sphingomyelinase to cellular plasma membranes leading to release of cholesterol. One 
hypothesis would be that SM acts as a molecular trap for cholesterol and SM storage is 
responsible for cholesterol elevation in NPC disease [11]. 
Sphingosine is a potent inhibitor of PKC and calcium channels. Sphingosine levels 
are increased in all tissues in NPC disease [11]. There is an increase of 12-fold in 
periphery and 4-fold in the brain. There is a higher possibility that sphingosine bases are 
involved in early stages of NPC1 pathology, since adding sphingosine to normal cells 
induces NPC phenotype. In fact, sphingosine is the only lipid (of all the storage lipids in 
NPC cells) that is capable of inducing a NPC phenotype in normal cells when added at the 
concentration found in NPC cells [44].  NPC1 inactivation leads to the rapid primary 
accumulation of sphingosine that causes a defect in lysosomal calcium storage, probably 
due to sphingosine mediated PKC inhibition. The lack of appropriate calcium release from 
the LE/Lys compartment leads to trafficking defects that in turn cause secondary storage 
of other lipids including cholesterol and GSL. Neurodegeneration may result from defects 
in all or any combination of these events (Figure 1.6). 
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Figure 1.6 - Putative pathogenic cascade of NPC1 dysfunction. Role of the accumulation of 
sphingosine in the disease. Adapted from [11]. 
 
 
3. Oxidative stress in neurodegenerative disorders 
 
As mentioned above, the pathogenic mechanism associated to the accumulation 
of intracellular lipids that leads to cell death in NPC disease is still unclear. However, there 
are some evidences that implicate oxidative stress in NPC [45] and other 
neurodegenerative disorders, such as Alzheimer disease, Parkinson disease, and 
amyotrophic lateral sclerosis [46]. 
Oxygen (O2) is indispensable for the majority of living organisms, as it is required 
for energy production in mitochondria. Molecular oxygen itself is not toxic, but its partial 
reduction can generate reactive oxygen species (ROS). During mitochondrial respiration, 
there is electron leakage from the electron transport chain that results in the generation of 
ROS. This process under physiologic conditions is the major intracellular source of ROS, 
although there are substantial controversies regarding the exact amounts of ROS 
produced at the different sites of the respiratory chain [47,48]. The main function of 
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mitochondria is the production of energy by oxidative phosphorylation. Mitochondria are 
responsible for producing most of the ATP necessary for cell functions. In addition 
mitochondria can produce and control the cellular redox state, and mantain intracellular 
calcium homeostasis. Oxidative stress damages mitochondrial DNA (mtDNA), and an 
already damaged mitochondria might incur more oxidative damage causing a vicious 
cycle that results in even more ROS production [49,50]. A change in the mitochondrial 
membrane potential is a key feature of the early stages of mitochondrial dysfunction [51]. 
A number of external agents can trigger ROS production, such as an increased oxygen 
pressure, ionizing radiation, environmental toxins (e.g., paraquat or menadione) or UV 
light [52]. 
ROS include superoxide anion (O2
), hydroxyl radical (OH) and hydrogen peroxide 
(H2O2). In the presence of reduced redox active transition metals, such as iron (Fe2+) and 
copper (Cu+), H2O2 is reduced to produce the highly reactive and powerful oxidant OH
(Fenton reaction). The oxidised form of the metal can then be reduced by the O2
, via 
Haber-Weiss reaction: 
 
Fenton reaction: Metaln+ + H2O2 ĺ0HWDOn+1 + OH + OH- 
 
Haber-Weiss reaction: Metaln+1 + O2 ĺ0HWDOn + O2 
 
 
Cellular response to oxidants depends on many factors, including cell type, the 
absolute level and duration of oxidant production, the specific intracellular site of ROS 
production, and the ROS species generated [53]. 
 To counterbalance the generation of ROS and prevent its harmful effects, cells 
have developed several strategies like the production antioxidant defences. These 
defences include enzymes that directly detoxify ROS (e.g., superoxide dismutases, 
catalase, glutathione peroxidases, thioredoxin peroxidases), proteins that act as redox 
regulators of protein thiols (e.g., thioredoxin) and small antioxidant molecules 
(e.g.,glutathione). In addition, enzymes with the same biochemical antioxidant activity can 
be found in different cellular compartments and they are responsible for specialized 
detoxification of ROS at specific compartments [54]. Under physiological conditions, a 
balance is established between ROS levels and cellular antioxidant defences. This allows 
the cell to restrains the pro-oxidant effects of ROS. But, if the ROS production is 
increased, or the antioxidant defences are reduced, cells face an imbalance of the 
homeostasis in favour of ROS. This will lead an oxidative stress and the concomitant 
accumulation of oxidative damages to lipids, DNA and proteins [54,55]. 
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The CNS is particularly sensitive to oxidative stress. This can be explained by 
several features of the CNS: the susceptibility to lipid peroxidation, because of the higher 
concentration of unsaturated fatty acids, the fact that neurons require large amounts of 
energy that leads to high oxygen consumption and ultimately production of ROS, and the 
lower levels of antioxidant defences, such as glutathione, compared with other organs 
[56,57]. Mitochondrial dysfunction leading to oxidative stress appears to be a major factor 
in many neurodegenerative diseases, such as Alzheimer disease [58] and Parkinson 
Disease [59], and pathologies associated with liver and cardiac damage [45]. 
 
3.1.  Oxidative stress in NPC 
 
Oxidative stress had been implicated in NPC. It was shown an imbalance in the 
intracellular redox state, both in fibroblasts from NPC patients and in experimentally-
induced NPC1 knockdown in vitro (using small interference RNA - siRNA) in primary 
cultures of fibroblasts [60]. An increase in ROS concentration was also found in human 
SHSY5Y neuroblastoma cells, induced with the same NPC1 knockdown, suggesting that 
probably the imbalance in the intracellular redox state would not be restricted to a single 
cell type [60]. There are also evidences of an increase in oxidative stress in vivo in the 
cerebellum of NPC1-/- mice [61].  
Mitochondrial dysfunction seems to have an important role in NPC disease. Fu 
and collaborators have shown that Coenzyme Q10 may contribute directly to NPC 
pathology. In the mitochondrial respiratory chain, CoQ10 plays an important role in the 
production of chemical energy, and an increase in ubiquinone-10 (oxidized) and the 
respective decrease in ubiquinol-10 (reduced) in NPC cells suggests mitochondrial 
dysfunction [62]. One study showed a decrease in catalase activity in several NPC 
models, leading to an increase of intracellular levels of ROS and lipid peroxidation [60]. 
Notably, antioxidant therapies failed to attenuate oxidative stress in NPC cells or animals 
[63,64]. 
Another study suggests that neuronal dysfunctions and degeneration in NPC1-/- 
mouse brains are caused by a decrease in mitochondrial membrane potential that leads to 
a reduction in ATP synthesis. In addition, mitochondrial dysfunctions have been 
associated to increased levels of cholesterol in the membrane of the mitochondria. When 
the levels of mitochondrial membrane cholesterol were decreased to the levels in NPC1+/+ 
cells, ATP synthesis and mitochondrial function were restored, supporting the hypothesis 
that increased mitochondrial cholesterol may cause dysfunctions per se [65]. 
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4. Yeast as a biological model for NPC 
 
The yeast Saccharomyces cerevisiae is a unicellular eukaryote fungus used as 
experimental model organism in scientific research. It has been used by men for a very 
long time in the production of economic valuable products. The similarities in organelles 
and biomolecules with higher eukaryotes makes yeast a useful model for the study of 
processes conserved throughout evolution [54]. S. cerevisiae has been used as a model 
to study biological processes such as cell cycle control [66], stress responses [55], or 
even mechanisms underlying neurodegenerative diseases  [67]. 
The first organism to have its genome fully sequenced was S. cerevisiae. The 
availability of the several databases that contain information about this microorganism 
genes and proteins, such as Saccharomyces Genome Database, provides a wide range 
of knowledge about protein-protein interaction, genetic interactions, protein functions and 
predict orthologues in other organisms [68]. The development of genomic and proteomic 
tools makes very easy to manipulate yeast genetically, and techniques for the 
manipulation are strongly optimized [69]. 
The yeast Saccharomyces cerevisiae has a single copy of NCR1, a NPC1 
orthologue. Ncr1p contains multiple transmembrane domains, such as NPC1 domain, a 
conserved SSD domain [70], and a cysteine-rich domain [71] (Figure 1.7). Moreover, 
NPC1 proteins have an extremely high functional conservation among species. Indeed, 
Ncr1p is able to suppress cholesterol and ganglioside accumulation when expressed in 
NPC1-deficient Chinese hamster ovary cells [70]. Most of the NPC1 mutations occur in 
amino acids that are conserved in yeast Ncr1p. Indeed, Ncr1p presents a rate of identity 
and similarity of 34% and 57%, respectively, when compared with human NPC1 [23,72]. 
Furthermore, of 105 identified miscoding patient mutations, 66% of the affected amino 
acids are conserved in yeast and of these, 50% are identical between Ncr1p and human 
NPC1 [71]. 
 
 
Figure 1.7 ± Comparisons of the NPC1 and Ncr1p protein sequences [70]. 
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Since this thesis will focus on the role of sphingolipid signalling in mitochondrial 
function and oxidative stress resistance in a yeast model of NPC, an overview of this 
subject will be provided in the next section. 
 
4.1. Sphingolipid signalling and mitochondria function in yeast 
 
In yeast the sphingolipid metabolism (Figure 1.7) has an unique entry point, 
catalysed by the serine palmitoyltransferase (SPT), and one exit point, catalysed by the 
sphingoid base phosphate lyase, which generates non sphingoid molecules [40]. The first 
reaction in sphingolipid biosynthesis occurs in the endoplasmic reticulum and consists in 
the condensation of serine and palmitoyl-CoA, catalysed by SPT, generating 3-
ketodihydrosphingosine (3-keto-DHS), CO2 and coenzyme A (CoA). Readily after its 
formation, 3-keto-DHS is reduced in the ER to DHS by a nicotinamide adenine 
dinucleotide phosphate (NADPH)-dependent 3-ketodihydrosphingosine reductase. DHS 
can produce phytoceramide by two different routes. It can be hydroxylated by 
Sur2p/Syr2p hydroxylase in order to form the other LCB, PHS, and then acylated to form 
phytoceramide by ceramide synthase. Alternatively, DHS can be acylated by ceramide 
synthase to form dihydroceramide prior to its hydroxylation into phytoceramide. 
Ceramides must be transported from the ER to the Golgi apparatus in order to receive 
their polar heads to form complex sphingolipids. The mechanism of transport in yeast is 
still unclear [42]. Yeast and mammalian complex sphingolipids differ in their polar heads. 
Yeast synthesizes inositophosphosphingolipids that may contain mannose whereas 
mammalian cells produce sphingomyelin through the transfer of choline phosphate to 
ceramide. The mammalian cells ceramide can be converted to glucosylceramide to yield 
later complex glycosphingolipids) or it can also be phosphorylated to ceramide-1-
phosphate [42,73].  
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Although the regulation of mitochondrial function is very complex, numerous 
studies suggest that signal transduction pathways modulated by nutrients and 
sphingolipids play a key role in this process (Figure 1.9). Components of these signalling 
pathways include the PIK-related Tor1p protein kinase subunit of the rapamycin-sensitive 
TORC1 complex [74], the catalytic subunit of the ceramide-activated protein phosphatase 
Sit4p [75], and the Sch9p kinase, a homolog of mammalian ribosomal S6 kinase and 
mammalian PKB/Akt [76]. 
 
 
 
Figure 1.9 - Crosstalk between nutrient and sphingolipid signalling pathways that control 
mitochondrial function. Tor1p resides in a multi-protein complex TORC1 and is activated by nutrients, in 
particular by amino acids. This protein by phosphorylation activates Sch9p and inactivates Sit4p. Sch9p and 
Sit4p are also regulated by sphingolipids, namely ceramide and phytosphingosine respectively. All proteins 
inactivate mitochondrial function, decreasing oxidative stress resistance and lifespan. 
 
4.1.1. Tor1p  
The Target of Rapamycin (TOR) is a serine-threonine protein kinase conserved in 
all the eukaryotes. Studies in yeast revealed that TOR resides in two distinct multi-protein 
complexes, TORC1 (sensitive to rapamycin), and TORC2 (insensitive to rapamycin). 
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These complexes function in separate signalling pathways and regulate distinct aspects of 
the cell growth. Together these pathways define the TOR signalling network [77].  
The activity of TORC1 is influenced by growth factors, energy and cellular stress. It 
positively controls proteins synthesis regulating ribosome biogenesis at multiple levels, 
translation of some genes, and metabolism (amino acids biosynthesis and glucose 
homeostasis) [78]. TORC1 activity is influenced by nutrients, mainly by the nitrogen 
source. The main suggestion for this connection is that treatment of cells with rapamycin 
has the same effects of nitrogen deprivation on transcription, development and 
metabolism. For instance both nitrogen deprivation and rapamycin treatment induce 
autophagy, exit from the cell cycle and growth arrest at G0, and changes in transcription 
of some genes [79]. Despite uncertainty in the position of TORC1 within the nutrient 
signalling pathway, TORC1 certainly plays a major role in transition between growth and 
quiescence. 
TORC1 can regulate directly important proteins such as Sit4p and Sch9p. These 
proteins have a role in oxidative stress resistance, chronological lifespan (CLS) and 
mitochondrial function [80].There are complex relationships between TOR signalling, 
mitochondrial function, ROS production, and yeast CLS. In fact, the deletion of TOR1 
increases CLS as well oxidative stress resistance [74,81,82]. The absence of Tor1p forces 
the yeast to make respiration instead of fermentation, increasing mitochondrial activity and 
decreasing the production of ROS. In contrast, the activation of this pathway induces an 
increase in ROS production, damaging the mitochondria, which in turn results in a higher 
production of ROS [83]. 
 
4.1.2. Sit4p 
In yeast, Sit4p is the catalytic subunit of the ceramide-activated protein 
phosphatase, a heterotrimeric complex that also includes Tpd3p and Cdc55p as 
regulatory subunits [84]. Sit4p is a serine-threonine protein phosphatase related to type 
2A family of protein phosphatases (PP2A), and it has a high homology to other protein 
phosphatases, including the fission yeast PP2A and human protein phosphatase 6 that 
are involved in cell cycle regulation. Sit4p has a role in the control of the Swi4p factor that 
regulates the transcription of G1 cyclin genes and is required for down regulation of cell 
functions that depend on Pkc1p, such as cell wall integrity pathway, cytoskeleton 
organization, and ribosomal gene expression [85,86]. 
Yeast cells lacking the Sit4p are unable to grow under anaerobic conditions, 
indicating that the energy produced by mitochondrial respiration is essential for their 
viability [87]. A recent study showed that loss of Sit4p suppresses the shortened CLS, 
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oxidative stress sensitivity and mitochondrial dysfunctions of cells lacking Isc1p protein, 
an orthologue of the mammalian neutral sphingomyelinase 2 [75]. 
 
4.1.3. Sch9p 
Sch9p is a serine-threonine kinase with possible homology to mammalian 
ribosomal S6 kinase (S6K) [88] or Protein Kinase B (PKB/AKT) [89]. The activation of 
Sch9p induces ribosome biogenesis genes and inhibits genes involved in carboxylic acid 
metabolism. Glucose affects Sch9p function, both by increasing the level of Sch9p in the 
cell and by inducing its phosphorylation Sch9p phosphorylation as also induced by stress 
conditions such as heat stress [73,90]. Sch9p protein can also be activated by 
sphingolipids such as phytosphingosine through Pkh1/2p pathway [73,80]. Nutrients, more 
specifically amino acids, can activate Sch9p through TORC1 pathway, promoting 
antagonistic effects when compared with rapamycin and starvation treatments (two known 
inhibitors of TORC1), which rapid lead to a dephosphorylation of Sch9p. In addition recent 
studies showed that TORC1 directly phosphorylates Sch9p at multiple sites in its C-
terminal domain [88]. 
Deletion of SCH9 gene leads to phenotypes similar to the observed in cells lacking 
Tor1p,improving mitochondrial function, decreasing ROS levels, extending CLS and 
increasing resistance to acid, thermal and oxidative stress conditions [74,76,88,91]. 
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Scope of the Work 
 
Previous studies implicate mitochondrial dysfunction and oxidative stress in NPC 
disease [60±62,65]. Moreover, changes in the level of sphingolipids have been described 
in NPC models [11]. 
Thereby, the present work aimed to: 
i. uncover the role of the yeast Ncr1p in oxidative stress resistance  
ii. characterize changes in mitochondrial function in 'ncr1 cells 
iii. characterize the role of Tor1p, Sit4p and Sch9p in the dysregulation of 
mitochondrial function and oxidative stress resistance in 'ncr1 cells 
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1. Yeast strains and growth conditions  
 
The Saccharomyces cerevisiae strains used in this study are listed in Table 3.1. 
Yeast cells were grown aerobically at 26 ºC in a gyratory shaker (at 140 rpm), with a ratio 
of flask volume / medium volume of 5:1, to early exponential phase (OD600nm=0.6). The 
growth media used were: yeast peptone dextrose, YPD, (1 % (wt/vol) yeast extract, 2 % 
(wt/vol) bactopeptone, 2 % (wt/vol) glucose); synthetic complete (SC) drop-out medium 
containing 2 % (wt/vol) glucose and 0.67 % yeast nitrogen base without amino acids and 
supplemented with appropriate amino acids or nucleotides (0.008 % (wt/vol) histidine, 
0.008 % (wt/vol) tryptophane, 0.04 % (wt/vol) leucine and 0.008 % (wt/vol) uracil) and 
minimal medium (0.67 % (wt/vol) yeast nitrogen base without aminoacids, 2 % (wt/vol) 
glucose), supplemented with appropriate amino acids and nucleotides (0.004 % (wt/vol) 
histidine, 0.004 % (wt/vol) methionine, 0.008 % leucine and 0.004 % (wt/vol) uracil)].  
For the spotting assay, cells were diluted to OD600nm=0.1 and fivefold serial 
dilutions were plated on supplemented with SC - 2 % (wt/vol)  glucose (control) or SC - 3 
% (wt/vol)  glycerol. 
Table 3.1 ± Yeast strains used in this work 
Strain Genotype  Reference/source 
BY4741 
ǻncr1 
ǻncr1 
BY4741 pRS316 
BY4741 pNCR1 
ǻncr1 pRS316 
ǻncr1 pNCR1 
ǻtor1 
ǻncr1ǻtor1 
ǻsit4 
ǻncr1ǻsit4 
ǻsch9 
ǻncr1ǻsch9 
W303a 
 
:Dǻncr1 
Mata, his3ǻleu2ǻmet15ǻura3ǻ 
%<ǻncr1::KanMX4 
%<ǻncr1::URA3 
BY4741 carrying pRS316 
BY4741 carrying pRS316-NCR1 
ǻncr1 carrying pRS316 
ǻncr1 carrying pRS316-NCR1 
%<ǻtor1::KanMX4 
%<ǻncr1::URA3 ǻtor1::KanMX4 
%<ǻsit4::KanMX4 
%<ǻncr1::URA3 ǻsit4::KanMX4 
%<ǻsch9::KanMX4 
%<ǻncr1::URA3 ǻsch9::KanMX4 
Mata, ura3-1, leu2-3, his3-11, trp1-1, ade2-1, 
can1-100  
:Dǻncr1::KanMX4 
EUROSCARF 
Vilaça, R  
This study 
Vilaça, R. 
Vilaça, R. 
Vilaça, R.  
Vilaça, R.  
EUROSCARF 
This study 
EUROSCARF  
This study 
EUROSCARF 
This Study 
[92] 
 
This study 
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2. Oxidative stress resistance 
 
Yeast cells were grown to exponential phase (OD600nm=0.6) and treated with H2O2 
for 1 h. Cell viability was determined by standard dilution plate counts on YPD medium 
containing 1.5 % agar. Colonies were counted after growth at 26 ºC for 3 days. Viability 
was expressed as the percentage of the colony-forming units (CFU).  
 
3. Genomic DNA extraction 
 
Cells (10 mL) were grown to stationary phase and harvested by centrifugation 
during 5 min at 4000 rpm. The pellet was collected, washed once and resuspended in 100 
ȝ/RIO\VLVEXIIHU (vol/vol) Triton X-100, 1 % (wt/vol) SDS, 100 mM NaCl, 10 mM Tris-
+&O S+   P0 ('7$ DQG  ȝ/ RI SKHQROFKORURIRUPLVRDP\O DOFRKRO 
Cells were lysed by vigorous shacking of the cell suspension in the presence of glass 
beads for 3 min (short pulses of 1 min were used, with 1 min intervals). The aqueous 
SKDVHZDV UHFRYHUHGDIWHU FHQWULIXJDWLRQDW  USPPLQ DQGȝ/RIFKORURIRUP
were added. The mixture was homogenized by vortexing 3 min (as described previously), 
VXSSOHPHQWHGZLWKȝ/7([P07ULVP0('7$S+DQGFHQWULfuged 
(14000 rpm, 5 min). The aqueous phase was washed with 1 mL of 100 % ethanol. After 
FHQWULIXJDWLRQUSPPLQWKHSHOOHWZDVUHVXVSHQGHGLQȝ/RI7([,WZDV
added 30 µg of RNAase and the mixture was incubated 5 min at 37 ºC. Then, 10 ȝ/RI
M ammonium acetate and 1 mL of 100 % ethanol were added. The DNA was collected by 
centrifugation (14000 rpm, 3 min), washed twice with 70 % (vol/vol) ethanol, dried and 
resuspended in appropriate water. The genomic DNA was quantified using a NanoDrop 
spectrophotometer (ND-1000, Thermo Scientific) and analyzed by gel electrophoresis in 
1.4 % (wt/vol) agarose. 
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4. PCR  
 
A PL[RIȝ/FRQWDLQLQJ[5HDFWLRQ%XIIHU7KHUPR6FLHQWLILFP00J&O2 
7KHUPR 6FLHQWLILF  P0 VHQVH SULPHU  P0 DQWLVHQVH SULPHU  ȝ0 G173V
(Fermentas), 1 U Taq Polymerase (Thermo Scientific), and 150 ng genomic DNA was 
prepared. All the primers used in this study except TOR1_amp_Fw and TOR1_amp_Rv 
have an annealing temperature of 55 ºC and an elongation of 2 min during 30 cycles. For 
the amplification of KanMX4 the annealing temperature was 58ºC, the elongation was 
2min20s, during 35 cycles. PCR products were analysed in agarose gel 0,8 % (wt/vol) 
using TAE 1 x as buffer, and DNA bands were compared to Gene Ruler Ladder Mix 
(Fermentas). 
 
5. Gene disruption 
 
The disruption of NCR1 using CaURA3 cassette was performed by homologue 
UHFRPELQDWLRQ LQ ǻncr1 (with KanMX4). The deletion fragment containing URA3 and 
flanking regions of KanMX4 was amplified, from the plasmid pAG61 containing the C. 
albicans URA3 ORF [93], by PCR using the primers CaURA3_amp_Fw and 
CaURA3_amp_Rv. The disruption of TOR1 JHQH LQ ǻncr1 cells was performed by 
homologous recombination, using a deletion fragment containing KanMX4 and the 
flanking regions of TOR1. This deletion fragment was amplified by PCR using the primers 
TOR1_amp_Fw and TOR1_amp_Rv (Table 3.2) and genomic DNA from ǻtor1 cells. For 
NCR1 JHQHGLVUXSWLRQLQǻsit4 DQGǻsch9 cells, a deletion fragment containing URA3 and 
the flanking regions of NCR1 was amplified by PCR using primers NCR1_amp_Fw and 
NCR1_amp_Rv (Table 3.2) and genomic DNA from ǻncr1 cells (with URA3). Purification 
of DNA from TAE agarose gel was performed with GFXTM PCR DNA and Gel Band 
Purification Kit (GE Healthcare). Cells were transformed by electroporation (as described 
below) and mutant cells were selected in rich medium (YPD) containing geneticin (TOR1 
deletion), or minimal medium lacking uracil (NCR1 deletion). Gene disruption was 
confirmed by PCR, using the fallowing pars of primers: TOR1_conf_Fw + 
IntKanMX4_conf_Rv or TOR1_conf_Fw + IntTOR1_conf_Rv (for TOR1 deletion); 
NCR1_conf_Fw + IntURA3_conf_Rv or NCR1_conf_Fw + IntNCR1_conf_Rv (for NCR1 
deletion) (Table 3.2). 
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Table 3.2 ± Primers used in this work 
Primers  Sequence  
CaURA3_amp_Fw 
CaURA3_amp_Rv 
TOR1_amp_Fw  
TOR1_amp_Rv 
NCR1_amp_Fw 
NCR1_amp_Rv 
TOR1_conf_Fw 
IntTOR1_conf_Rv 
IntKanMX4_conf_Rv 
NCR1_conf_Fw 
IntNCR1_conf_Rv 
IntURA3_conf_Rv 
TCCTTGACAGTCTTGACG 
GTATAGCGACCAGCATTC 
GAGAATCATTACCGGCGAAA 
TACGAACACGTTTGGTGATG 
CCGTGGCTAATGTCACAACA 
TTACGAGTGAAGCGTTCTGG 
CAAAGAGTAAGAGGGTCCTTGGG 
GAACAGCCCCTACCCTAGTGCT 
TGCTGTTTTGCCGGGGAT 
AAGGTGCGAAATGACGGAAGA 
CGTCGTCCACAATCATTGCCC 
CCCAGTGACACCATGAGCATTAG 
*Fw - Forward /Rv - Reverse 
 
6. Yeast electroporation  
6.1. Preparation of electrocompetent cells 
Cells were grown in 50 mL of YPD medium to an OD600nm = 1.3 ± 1.5, harvested, 
and resuspended in 10 mL of 10 mM Tris 1 mM EDTA 100 mM lithium acetate pH 7.5 and 
JHQWO\VKDFNHGGXULQJPLQDW&7KHQȝ/RIM DTT was added and cells 
were shacked 15 min at 30 ºC. Ice-cold sterile water was added for a final volume of 50 
mL and cells were centrifuged at 4 ºC. Cells were washed first with 25 mL of ice-cold 
sterile water and then with 2 mL of 1 M sorbitol (4 ºC), DQGUHVXVSHQGHGLQȝ/RI0
sorbitol (4 ºC). 
 
6.2. Electro-transformation and plating  
(OHFWURFRPSHWHQWFHOOV ȝ/ZHUHPL[HGZLWKȝ/RIGHOHWLRQ IUDJPHQW 
ȝJDQGLQFXEDWHGRQLFHIRUPLQXWHV7KHPL[WXUHZDVWUDQVIHUUHGWRSUHFKLOOHGVWHULOH 2 
PPHOHFWURSRUDWLRQFXYHWWH$QHOHFWULFSXOVHN9ȝ)DQGȍZDVDSSOLHG LQ
parallel using an electroporation system (BioRad). After the pulse delivery, 1 mL of 
selective minimal medium containing 1 M sorbitol was immediately added and cells were 
gently shacked for 4 h at 26 ºC. Cells were plated in selective medium and grown at 26 ºC 
for 3 days. 
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7. Oxidative stress markers  
7.1. Quantification of ROS 
This method is based on an in vivo intracellular oxidation of the oxidant-sensitive 
probe dihydroethidium (DHE) (Molecular Probe, Life Technologies).  
Yeast cells were grown to exponential phase, exposed to 1.5 mM of H2O2 for 50 
minutes at 26 ºC and labelled with 1 µL of 5 mM DHE for 10 minutes at 26ºC. Cells were 
washed twice with filtered PBS and sonicated. Fluorescence was measured on the FL-3 
channel of a Becton-Dickinson FACSort flow cytometer using 15.000 events. The data 
was analyzed using the FlowJo software (Tree Star) and the percentage of positive cells 
was quantified, using as control the autofluorescence of the cells. 
 
7.2. Lipid peroxidation  
Lipid peroxidation was determined by quantifying thiobarbituric acid reactive 
substances as described [94]. This method is based on the acid-catalyzed decomposition 
of lipid peroxides to malondialdehyde (MDA) which reacts with thiobarbituric acid to form a 
red chromogen.  
Yeast cells were harvested by centrifugation and yeast extracts were prepared in 
50 mM potassium phosphate buffer (pH 7.0), by vigorous shaking of the cell suspension in 
the presence of glass beads for 3 min. TCA were added and the shaking were performed 
for 2 min. Short pulses of 1 min were used, with 1 min intervals on ice.  Briefly, the 
following mixture was made for each sample: 100 µL sample or buffer (control) + 100 µL 
0.1 M EDTA + 600 µL thiobarbituric acid solution (26 mM TBA, 0.25 M HCl, 15 % TCA) + 
8.1 µL 50 mM BHT. The mixtures were boiled for 15 min and chilled out at ambient 
temperature. Absorbance was measured at 532 nm [95]. The MDA concentration was 
HVWLPDWHGXVLQJİ [0-1 cm-1. 
 
7.3. Carbonylation  
Protein oxidation was determined by immunodetection of protein carbonyls, as previously 
described [96].This method is based on the reaction of carbonyl groups with 2,4 - 
dinitrophenylhydrazine (DNPH) to form  2,4 ± dinitrophenylhydrazone (DNP). 
Yeast cells were harvested by centrifugation and yeast extracts were prepared in 
50 mM potassium phosphate buffer (pH 7.0) containing protease inhibitors (Complete, 
Mini, EDTA-free Protease Cocktail Inhibitor Tablets; Boehringer Mannhein), by vigorous 
shaking of the cell suspension in the presence of glass beads for 5 min. Short pulses of 1 
min were used, with 1 min intervals on ice. Cell debris was removed by centrifugation at 
Material and Methods 
34 
13000 rpm for 15 min and protein content was determined by the method of Lowry [97], 
using bovine serum albumin as a standard.  
 A volume corresponding to 40 ȝg of protein was mixed with 1 volume of 12 % 
(wt/vol) SDS. After a short spin, 2 volumes of 20 mM DNPH 10 % (vol/vol) TFA were 
added and mixed. The mixture was incubated for 30 min at room temperature and in the 
dark. The samples were neutralized with 1.5 volumes of 2 M Tris 30 % (vol/vol) glycerol 
19 % (vol/vol) ȕ-mercaptoethanol.  
Proteins derivatized with DNPH (0.1 ȝg) were slot blotted onto a PVDF membrane 
(Hybond PTM, GE Healthcare) previously activated with 100 % methanol. Alternatively, 12 
µg of derivatized proteins were separated by electrophoresis using 10 % polyacrylamide 
gel, LMW Calibration Kit for SDS Electrophoresis (GE Healthcare) was used as protein 
standards. Proteins were transferred to a nitrocellulose membrane (Hybond-ECLTM, GE 
Healthcare) previously hydrated with transfer buffer (39 mM glycine, 48 mM Tris, 0.0375 
% (wt/vol) SDS, 20 % (vol/vol) methanol). Blotting was performed at 0.8 mA/cm2 for 1 h. 
After blotting, the nitrocellulose membranes were stained with Ponceau S (0,6 % (wt/vol) 
of Ponceau S,  3 % (wt/vol) TCA and 3 % (wt/vol) sulfosalicylic acid acid ) to visualize 
proteins. Slot blot and western blot membranes were blocked for 1 h with 5 % (wt/vol) milk 
powder in TPBS (0.065 % (wt/vol) Tween-20, 0.4 % (wt/vol) NaCl, 0.01 % (wt/vol) KCl, 
0.09 % (wt/vol) Na2HPO4.2H2O, 0.012 % (wt/vol) KH2PO4) and incubated overnight with 
the primary antibody rabbit IgG anti-DNP (1:1500; Sigma). Membranes were washed 
twice with TPBS and incubated for 1 h with the secondary antibody goat anti-rabbit IgG-
peroxidase (1:5000; Sigma). Membranes were washed twice with TPBS and with TBS 
(0.4 % (wt/vol) NaCl, 0.01 % (wt/vol) KCl, 0.09 % (wt/vol) Na2HPO4.2H2O, 0.012 % 
(wt/vol) KH2PO4). Immunodetection were performed by chemiluminescence, using ECLTM 
Western Blotting Detection Reagents (GE Healthcare). Membranes were exposed to a 
Hybond-ECL film (GE Healthcare), and the film was developed. 
 
8. Statistical analyses  
 
Data were analysed in GraphPad Prism Software v5.01 (GraphPad Software) and 
expressed as mean values ± SD from at least three independent experiments. Values 
werH FRPSDUHG E\ 6WXGHQW¶V W-test p< 0.05; **, p< 0.01; ***, p< 0.001.
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1. Ncr1p deficiency decreases resistance to hydrogen peroxide   
 
To analyse the resistance of cells lacking Ncr1p to oxidative stress conditions, S. 
cerevisiae  BY4741 (parental) and ǻncr1 mutant cells were grown to exponential phase 
(OD600nm=0.6) and treated for 1 hour with 0.5 or 1.5 mM H2O2. This oxidant agent is widely 
used to induce an acute oxidative stress.  
As expected, the results showed a dose-dependent decrease in the viability of the 
parental cells (Figure 4.1 A). The deletion of NCR1 significantly decreased the resistance 
of yeast cells to H2O2 for both concentrations.  
We also evaluated H2O2 resistance of cells lacking Ncr1p in another background 
strain (W303a). The results obtained were similar to those described for the BY4741 
strain, suggesting that the oxidative stress sensitivity of ǻncr1 mutant cells is not strain 
related (Figure 4.1 B).  
 
 
 
 
Figure 4.1- Effect of NCR1 deletion in oxidative stress resistance. S. cerevisiae BY4741 (A) or W303 (B) 
strains and its isogenic ǻncr1 mutant cells were grown to exponential phase in SC-glucose medium and 
exposed H2O2 for 1 h. Cell viability was expressed as the percentage of the colony-forming units (treated cells 
vs. untreated cells). Data were expressed as mean values ± SD of at least three independent experiments. 
Values were compared by Student´s t-test. **,p< 0.01; ***, p< 0.001 
 
 
 
(A) 
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7RHYDOXDWHLIWKHKLJKHUVHQVLWLYLW\RIWKHǻncr1 mutant cells to hydrogen peroxide 
was specifically related with the absence of Ncr1p, oxidative stress was assessed in 
BY4741 and ǻncr1 mutant cells transformed with pRS316 (empty vector) or pRS316-
NCR1 (plasmid expressing Ncr1p under its own promoter).  
The results show that NCR1 expression in parental cells did not affect the 
resistance to H2O2 (Figure 4.2). However, the viability of ǻncr1 mutant cells expressing 
NCR1 and treated with 0.5 or 1.5 mM H2O2 was significantly higher (37 % and 14 %, 
respectively) to the observed in ǻncr1-pRS316 cells (23 % and 5 %, respectively). These 
results show that NCR1 expression partially suppresses H2O2 VHQVLWLYLW\RIǻncr1 mutant 
cells, confirming the hypothesis that Ncr1p is important to H2O2 resistance. 
 
 
 
 
Figure 4.2- Effect of NCR1 expression in oxidative stress resistance. S. cerevisiae %<DQGǻncr1 
cells transformed with pRS316 or pRS316-NCR1 were grown to exponential phase in SC-glucose medium 
lacking uracil and exposed to 0.5 and 1.5 mM H2O2 for 1 h. Cell viability was expressed as the percentage of 
the colony-forming units (treated cells vs. untreated cells). Data were expressed as mean values ± SD of at 
least three independent experiments. Values were compared by Student´s t-test.*, p< 0.05; ***, p< 0.001 
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2. Oxidative stress markers  
 
Hydrogen peroxide-induced cell death is associated with an increase in the levels 
of oxidative stress markers [96]. Therefore, we investigated if the sensitivity of ǻncr1 
mutant cells to H2O2 was associated with higher levels of oxidative stress markers, 
namely reactive oxygen species, lipid peroxidation and protein carbonylation.  
 
2.1. Intracellular oxidation  
 
The intracellular levels of ROS were measured using dihydroethidium (DHE), a 
non-fluorescent probe that is highly sensitive to superoxide radicals. The reaction of DHE 
with superoxide generates ethidium [98], a fluorescent dye that can be detected by flow 
cytometry or spectrofluorimetry.  
To test if the lower resistance of the cells lacking Ncr1p to H2O2 was associated 
with higher levels of intracellular ROS, both parental cells and ǻncr1 mutant cells were 
maturated or treated with 1.5 mM of H2O2, were labelled with DHE. Unlabelled cells were 
used as control (autofluorescence).  
The quantification of DHE positive cells by fluorescence-activated cell sorting 
(FACS) analysis showed an increase with hydrogen peroxide treatment (Figure 4.3). 
However, this increase was significantly higher in ǻncr1 mutant cells. Moreover, the basal 
levels of ROS were higher in ǻncr1 mutant cells, compared with parental cells (Figure 
4.3). 7KHVHUHVXOWVVXJJHVWWKDWWKHVHQVLWLYLW\RIǻncr1 mutant cells to H2O2 is associated 
with higher levels of intracellular ROS. 
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Figure 4.3 ± Quantification of intracellular ROS. S. cerevisiae %< DQG ǻncr1 cells were grown to 
exponential phase, treated with 1.5 mM of H2O2 for 50 minutes labelled with DHE for 10 minutes and analysed 
by FACS as described in methods. (A) ± FACS plot analysis of cells untreated and treated with H2O2 (B) ± 
Quantification of the intracellular ROS levels using information from FACS plots. The % of positive cells was 
quantified by Flowjo software analyses. Data are mean ± SD of at least three independent experiments. 
Values were compared by Student´s t-test. **, p< 0.01; ***, p< 0.001 
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2.2. Lipid peroxidation  
 
Lipid peroxidation was assessed in BY4741 and ǻncr1 mutant cells untreated or 
treated for 1 hour with 1.5 mM H2O2. In parental cells, exposure to H2O2 increased 43 % 
lipid peroxidation (Figure 4.4). This increase was significantly higher (95 %) in ǻncr1 
mutant cells. In addition, the basal levels of lipid peroxides in the mutant cells were 64 % 
higher to the observed in parental cells (Figure 4.4). These results suggest that the 
VHQVLWLYLW\ RI ǻncr1 mutant cells to H2O2 is associated with higher levels of lipid 
peroxidation. 
 
 
 
Figure 4.4 ± Lipid peroxidation. S. cerevisiae BY4741 DQGǻncr1 mutant cells were grown to exponential 
phase and treated with 1.5 mM H2O2 for 1h. Lipid peroxidation was quantified as described in methods. Data 
were normalized for untreated BY4741 cells. Values are mean ± SD of at least three independent 
experiments. Values were compared by Student´s t-test.*, p< 0.05; ***, p< 0.001 
 
2.3. Protein carbonylation  
 
Protein oxidation can be induced by ROS and products of lipid peroxidation and 
include the oxidation of aminoacids and cofactors. The aminoacids more prone to 
oxidation are tryptophan, tyrosine, lysine, arginine, proline, histidine, methionine and 
cysteine [55]. The protein carbonyl content has been widely used as a biomarker of 
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oxidative stress mainly because of its early formation and the relative stability of 
carbonylated proteins [99]. 
 To evaluate protein oxidation, S. cerevisiae BY4741 and ǻncr1 mutant cells were 
treated with 1.5 mM H2O2, and protein extracts were slot-blotted to a PVDF membrane or 
resolved by SDS-PAGE and transferred to a nitrocellulose membrane.  The 
immunodetection of protein carbonyls showed a 4-fold increase in parental cells exposed 
to H2O2 (Figure 4.5). Ncr1p deficiency significantly increased H2O2-induced protein 
oxidation: after exposure to this oxidant, carbonyl content increased 7-fold in ǻncr1 
mutant cells. In addition, the basal levels of protein carbonylation were 2-fold higher in 
ǻncr1 cells, when compared to parental cells. These results suggest that the sensitivity of 
ǻncr1 mutant cells to H2O2 is also associated with higher levels of protein carbonylation. 
 
 
 
 
 
Figure 4.5 ±Protein carbonylation. S. cerevisiae %<DQGǻncr1 cells were grown to exponential phase 
and treated with1.5 mM H2O2 for 1 h. Protein extracts were derivatized with DNPH and (A) ± separated by 
SDS-PAGE, blotted into a nitrocellulose membrane and stained with Ponceau S (loading control). (B) ± Slot-
blotted into a PVDF membrane. Immunodetection was performed using an anti-DNP antibody, as described in 
methods. The quantification of the slot-blot bands was performed by densitometry. Data were normalized for 
untreated BY4741. Values are mean ± SD of at least three independent experiments. Values were compared 
by Student´s t-test.*, p< 0.05; ***, p< 0.001. 
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3. Menadione resistance  
 
To evaluate if the oxidative stress sensitivity of ǻncr1 mutant cells was specific for 
hydrogen peroxide, cellular resistance to menadione, a superoxide generating drug, was 
also investigated. Menadione is a quinone that has been used as an agent for therapy of 
diseases like cancer. It is reduced by several enzymes, including microsomal NADPH-
cytochrome P-450 redutase or mitochondrial NADH ubiquinone oxidoredutase, producing 
semiquinone radicals. Under aerobic conditions, these radicals participate in redox cycling 
to generate superoxide radicals [100]. 
To study menadione resistance, both parental and ǻncr1 mutant cells were treated 
for 1 hour with three different concentrations of this oxidant agent. The results show that 
menadione resistance of ǻncr1 mutant cells was similar to the observed in parental cells 
(Figure 4.6). This suggests that ǻncr1 mutant cells are specifically more sensitive to H2O2. 
 
 
 
Figure 4.6 - Effect of menadione in oxidative stress resistance. S. cerevisiae %< DQGǻncr1 cells 
were grown to exponential phase and exposed to 50, 100 and 200 mM of menadione (MD) for 1 h. Cell 
viability was expressed as the percentage of the colony-forming units (treated cells vs. untreated cells). Data 
were expressed as mean values ± SD of at least three independent experiments. Values were compared by 
Student´s t-test. 
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4. Mitochondrial dysfunction 
 
Mitochondria are important for oxidative stress resistance. Previous work 
performed in our laboratory suggest that Ncr1p deficiency leads to mitochondrial 
dysfunction, as shown by the incapacity of these cells to grow in non-fermentable carbon 
sources, like glycerol, the decrease of cytochrome c oxidase activity and the 
destabilization of the mitochondrial network (Vilaça et al., unpublished). Several proteins 
such as Tor1p, Sit4p and Sch9p have been implicated in the regulation of mitochondrial 
function. The absence of these proteins increases mitochondrial respiration and 
decreases the production of ROS whereas their activation has opposite effects [83]. 
To test if the activation of one of these proteins signalling pathway could be 
associated with the mitochondrial dysfunction observed in cells lacking Ncr1p, 
ǻncr1ǻtor1, ǻncr1ǻsit4, and ǻncr1ǻsch9 double mutants were constructed. TOR1 was 
disrupted by homologous recombination, using a deletion fragment containing KanMX4 
and the flanking regions of this gene (Fig. 4.7) and the ǻncr1ǻtor1 mutants were selected 
in rich medium (YPD) containing geneticin. Gene deletion was confirmed by PCR.  The 
ǻncr1ǻsit4 and ǻncr1ǻsch9 double mutant were constructed deleting NCR1 in ǻsit4 and 
ǻsch9 cells. Gene disruption was also performed by homologous recombination, using a 
deletion fragment containing URA3 and flanking regions of NCR1. The double mutants 
were selected in minimal medium without uracil.  
 
 
 
Figure 4.7 ± Schematic representation of gene disruption by homologous recombination. 
 
 
The deletion of TOR1 was confirmed by PCR, using genomic DNA isolated from 
putative ǻncr1ǻtor1 double mutants or from BY4741 (negative control) and ǻtor1 (positive 
control) cells, and the following primers: (1) TOR1_conf_Fw and IntTOR1_conf_Rv 
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(amplifies a fragment of 1011 bps using gDNA from cells containing TOR1); (2) 
TOR1_conf_Fw and IntKanMX4_conf_Rv (amplifies a fragment of 1500 bps using gDNA 
from cells deleted for TOR1). The TOR1 gene was confirmed in BY4741 cells (set of 
primers 1), as expected, but not in ǻtor1 cells or in the ǻncr1ǻtor1 double mutants. The 
results using the set of primers 2 confirmed the deletion of TOR1 in WKHǻncr1ǻtor1 double 
mutants and LQǻtor1 cells (positive control) (Figure 4.8). 
 
 
 
 
Figure 4.8 ± Confirmation by PCR of TOR1 deletion. S. cerevisiae BY4741 and ǻtor1 cells, as well as 
ǻncr1ǻtor1 cells were grown to stationary phase, genomic DNA was extracted and PCR was performed as 
described in methods, using the following primers:  1- TOR1_conf_Fw + IntTOR1_conf_Rv; 2 ± 
TOR1_conf_Fw + IntKanMX4_conf_Rv. The PCR products were analysed by electrophoresis using a 0.8% 
agarose gel. DNA bands were compared to Gene Ruler Ladder Mix. 
 
 
 
 
A similar strategy was followed to confirm NCR1 deletion, using genomic DNA 
isolated from putative ǻncr1ǻsit4 RU ǻncr1ǻsch9 double mutants or from BY4741 
(negative control) and ǻncr1 (positive control) cells, and the following primers: (3) 
NCR1_conf_Fw and IntNCR1_conf_Rv (amplifies a fragment of 1323 bps using gDNA 
from cells containing NCR1); (4) NCR1_conf_Fw and IntURA3_conf_Rv (amplifies a 
fragment of 1320 bps using gDNA from cells deleted for NCR1). The NCR1 gene was 
confirmed in BY4741 cells (set of primers 3), as expected, but not in ǻncr1 cell or in 
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ǻncr1ǻsit4 and ǻncr1ǻsch9 double mutants. The results using the set of primers 4 
confirmed the deletion of NCR1 in the both double mutants (ǻncr1ǻsit4 and ǻncr1ǻsch9 
cells) and in the positive control cells (ǻncr1) (Figure 4.9.A and B). 
 
 
 
Figure 4.9 ± Confirmation by PCR of NCR1 deletion in (A) ± ǻsit4 cells and (B) ± ǻsch9 cells. S. 
cerevisiae BY4741, ǻsit4 and ǻsch9 cells, as well ǻncr1ǻsit4 cells and ǻncr1ǻsch9 cells were grown to 
stationary phase, genomic DNA was extracted and PCR was performed as described in methods, using the 
following primers:  3 - NCR1_conf_Fw + IntNCR1_conf_Rv; 4 ± NCR1_conf_Fw+ IntURA3_conf_Rv. The 
PCR products were analysed by electrophoresis using a 0.8% agarose gel. DNA bands were compared to 
Gene Ruler Ladder Mix. 
 
4.1. Inactivation of SIT4 or SCH9, in contrast with TOR1 gene, supresses H2O2 
sensitivity and growth defects on glycerol disSOD\HGE\ǻncr1 cells 
To test if deletion of TOR1, SIT4 or SCH9 suppresses mitochondrial dysfunction 
phenotype associated to Ncr1p deficiency, parental cells, ǻncr1, ǻtor1, ǻsit4 and ǻsch9 
single mutants, and ǻncr1ǻtor1, ǻncr1ǻsit4 and ǻncr1ǻsch9 double mutant cells were 
grown in SC-glucose medium to exponential phase, diluted  to an O.D.600nm=0.1 and 
plated in solid SC medium containing glucose or glycerol as carbon source. Both parental 
cells (BY4741), ǻtor1, ǻsit4 and ǻsch9 mutant cells were able to grow in the presence of 
glucose or glycerol.  As expected, ǻncr1 mutant cells were not able to grow in SC-glycerol 
(Figures 4.10A, 4.11A and 4.13A). This phenotype was not reverted by TOR1 deletion.  
Moreover, ǻncr1ǻtor1 cells displayed a high sensitivity to H2O2, as observed in ǻncr1 
single mutants (Figure 4.10B). These results suggest that the TORC1 pathway is not 
DVVRFLDWHGZLWKWKHORZUHVLVWDQFHRIǻncr1 mutant cells to H2O2. 
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Figure 4.10 ± Deletion of TOR1 does not suppress ǻncr1 phenotypes. (A) ± S. cerevisiae %<ǻncr1, 
ǻtor1 and ǻncr1ǻtor1 cells were grown to exponential phase, diluted  to a O.D600=0,1 and fivefold serial 
dilutions were plated in SC-medium containing glucose  or  glycerol as carbon source. (B) ± Yeast cells were 
grown to exponential phase and exposed to 0.5 and 1.5 mM H2O2 for 1 h. Cell viability was expressed as the 
percentage of the colony-forming units (treated cells vs. untreated cells). Data were expressed as mean 
values ± SD of at least three independent experiments. Values were compared by Student´s t-test.*, p< 0.05; 
**, p< 0.01;  
 
In contrast, the deletion of SIT4 suppressed the respiratory defects and H2O2 
sensitivity of ǻncr1 mutant cells (Figure 4.11). Consistent with published data, ǻsit4 
mutant cells presented a higher resistance to this drug, compared to the observed in 
parental cells (Figure 4.11B). These results suggest that the pathway involving Sit4p is 
associated with ǻncr1 mutant cells phenotype.  
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Figure 4.11 ± Deletion of SIT4 suppresses ǻncr1 phenotypes. (A) ± S. cerevisiae %<ǻncr1 , ǻsit4 
and ǻncr1ǻsit4 cells were grown to exponential phase, diluted  to a O.D600=0,1 and fivefold serial dilutions 
were plated in SC-medium containing glucose  or  glycerol as carbon source. (B) ±Yeast cells were grown to 
exponential phase and exposed to 0.5 and 1.5 mM H2O2 for 1 h. Cell viability was expressed as the 
percentage of the colony-forming units (treated cells vs. untreated cells). Data were expressed as mean 
values ± SD of at least three independent experiments. Values were compared by Student´s t-test. ***, p< 
0.001 
 
To test if the increase in the resistance of the ǻncr1ǻsit4 double mutant cells to 
H2O2 was associated with lower levels of intracellular ROS, ǻsit4 and ǻncr1ǻsit4 mutant 
cells were treated with 1.5 mM H2O2 for 50 minutes and subsequently labelled with DHE. 
The results showed an increase of DHE-positive cells induced by H2O2 that was similar in 
both ǻsit4 and ǻncr1ǻsit4 mutant cells (Figure 4.12A). However, this increase was 
significantly lower to the observed in ǻncr1, which is consistent with the higher H2O2 
resistance exhibited by ǻVLW and ǻncr1ǻsit4. This result further supports the hypothesis 
that Sit4p is involved in mitochondrial dysfunction associated with Ncr1p deficiency.  
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Figure 4.12 - Quantification of intracellular ROS. S. cerevisiae %<ǻncr1, ǻsit4 and ǻncr1ǻsit4 cells 
were grown to exponential phase, treated with 1.5 mM of H2O2 for 50 minutes labelled with DHE for 10 
minutes and analysed by FACS as described in methods. (A) ± FACS plot analysis of cells untreated and 
treated with H2O2 (B) ± Quantification of the intracellular ROS levels using information from FACS plots. The 
% of positive cells was quantified by Flowjo software analyses. The values for BY4741 and ǻncr1 cells are 
from Fig 4.3. Data are mean ± SD of at least three independent experiments. Values were compared by 
Student´s t-test.*, p< 0,05;***, p< 0.001 
 
 
In the same way, the deletion of SCH9 suppressed the respiratory defects and 
H2O2 sensitivity of ǻncr1 mutant cells (Figure 4.13). As expected ǻsch9 mutant cells 
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presented a lower sensitivity to this drug, compared to the observed in parental cells 
(Figure 4.13B). These results suggest that the pathway involving Sch9p is also associated 
with ǻncr1 mutant cells phenotype.  
 
 
 
Figures 4.13 ± Deletion of SCH9 suppress ǻncr1 phenotypes. (A) ± S. cerevisiae %<ǻncr1, ǻsch9 
and ǻncr1ǻsit4 cells were grown to exponential phase, diluted  to a O.D600=0,1 and fivefold serial dilutions 
were plated in SC-medium containing glucose  or  glycerol as carbon source. (B) ±Yeast cells were grown to 
exponential phase and exposed to 0.5 and 1.5 mM H2O2 for 1 h. Cell viability was expressed as the 
percentage of the colony-forming units (treated cells vs. untreated cells). Data were expressed as mean 
values ± SD of at least three independent experiments. Values were compared by Student´s t-test. **, p< 0.01; 
***, p< 0.001 
 
This increase in the resistance of the ǻncr1ǻsch9 double mutant cells to H2O2 was 
associated with lower levels of intracellular ROS. The results showed an increase of DHE-
positive cells induced by H2O2 that was similar in both ǻsch9 and ǻncr1ǻsch9 mutant 
cells but significantly lower to the observed in parental or ǻncr1 cells (Figure 4.14). This 
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supports the hypothesis that Sch9p is involved in mitochondrial dysfunction associated 
with Ncr1p deficiency.  
 
 
Figure 4.14 - Quantification of intracellular ROS. S. cerevisiae %<ǻncr1, ǻsch9 and ǻncr1ǻsch9 cells 
were grown to exponential phase, treated with 1.5 mM of H2O2 for 50 minutes labelled with DHE for 10 
minutes and analysed by FACS as described in methods. (A) ± FACS plot analysis of cells untreated and 
treated with H2O2 (B) ± Quantification of the intracellular ROS levels using information from FACS plots. The 
% of positive cells was quantified by Flowjo software analyses. The values IRU%<DQGǻQFUFHOOVDUH
from Fig 4.3. Data are mean ± SD of at least three independent experiments. Values were by Student´s t-test. 
**, p< 0.01; ***, p< 0.001 
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Discussion 
 
Sphingolipid storage diseases have been a main topic of research in the last 
years. The molecular pathology of these disorders has been subject of study in an attempt 
to understand the processes underlying these diseases. 
Niemann-Pick type C is an autosomal recessive lipid storage disease 
characterized by hepatosplenomegaly and severe progressive neurological dysfunction 
[2]. The clinical spectrum of NPC is extremely heterogeneous, and at the cellular level it is 
characterized by unique abnormalities in intracellular transport and accumulation of 
endocytosed cholesterol in lysosomes or late endosomes [28]. It can be caused by 
mutations in two different proteins, namely NPC1 and NPC2 that seem to mediate the 
proper intracellular lipid transport through pathways that remain unclear [1]. 
Reactive oxygen species are normal by-products of aerobic metabolism and are 
mainly produced by leakage of electrons in the mitochondrial electron transport chain [48]. 
Accumulation of ROS due to perturbation of control mechanisms can result in the 
accumulation of mutations, premature ageing and cell death. Excess of oxidative stress is 
implicated in several neurodegenerative disorders including NPC [45,46]. Studies using 
different NPC cellular models [60], as well as in mice tissues [101] including NPC-/- mice 
brain [63] suggest that oxidative stress as an important role in the pathophysiology of 
Niemann-pick type C disease. However, the role of oxidative stress in this and other 
neurodegenerative disorders [46] is still unclear, and it is still unknown if changes in redox 
homeostasis are cause or consequence of neurons degeneration [102].  
In this work, we investigated the role of Ncr1p, the yeast orthologue of human 
NPC1 protein [71], in oxidative stress resistance. Our results show that cells lacking Ncr1p 
were more sensitive to oxidative stress induced by H2O2, but not by menadione, a 
superoxide generating drug. This phenotype was not strain specific and was partially 
rescued by NCR1 expression, indicating that it is related to Ncr1p deficiency.    
Consistent with the hypersensitivity to H2O2 ǻncr1 mutant cells showed higher 
levels of oxidative stress markers, such as ROS, lipid peroxidation and protein 
carbonylation. Other studies performed in our laboratory showed that Ncr1p deficiency 
leads to a significant decrease in the levels of glutathione and in the activity of cytosolic 
catalase and mitochondrial superoxide dismutase (Vilaça et al., unpublished). Lower 
levels of antioxidant defences were also described in different NPC models, including a 
decrease of glutathione content in NPC mice livers [101] and of catalase activity in 
fibroblasts from NPC patients and in experimentally-induced NPC1 knockdown in primary 
cultures of fibroblasts or  human SHSY5Y neuroblastoma cells [60]. Thus, the decrease in 
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antioxidant defences may contribute to an increase in ROS levels and accumulation of 
oxidized molecules. Lipids exhibit a high susceptibility to oxidation, generating reactive 
products that will extend the pro-oxidant effects of ROS by damaging DNA and proteins 
[54]. Damaged proteins that cannot be repaired must be targeted to proteolytic systems to 
prevent the accumulation of proteins aggregates. Failure in oxidised proteins clearance 
can contribute to mitochondrial dysfunctions, further increasing ROS production [50,55].  
We hypothesize that the increase of intracellular oxidation in cells lacking Ncr1p is 
related with mitRFKRQGULDOG\VIXQFWLRQ,QGHHGRXUODEVKRZHGWKDWǻncr1 mutant cells are 
unable to grow in non-fermentable carbon sources, which require functional mitochondria, 
and display mitochondrial fragmentation and destabilization of mitochondrial membrane 
potential (Vilaça et al., unpublished). Some authors have demonstrated impaired 
mitochondrial function in other NPC models. NPC1-/-   mice exhibit a decrease in 
mitochondrial membrane potential associated with a decrease in the synthesis of ATP. 
This is due to an increase in the concentration of cholesterol in the mitochondrial 
membrane, altering its fluidity [65]. Mari and co-workers have reported a decrease of 
mitochondrial GSH in NPC hepatocytes while the cytosolic GSH remains unaltered [103]. 
The increase in mitochondrial cholesterol seems to influence the transport of GSH to the 
mitochondria, since it depends on the membrane fluidity [45]. Another study showed an 
increase in ubiquinone-10 (oxidized form) and the respective decrease in ubiquiol-10 
(reduced form), an imbalance that suggests mitochondrial dysfunctions [62]. 
A process that is associated to oxidaWLYH VWUHVV LV DJHLQJ ³7KH )UHH 5DGLFDO
7KHRU\ RI $JHLQJ´ OLQNV PLWRFKRQGULDO G\VIXQFWLRQ WR RYHUSURGXFWLRQ RI 526 FDXVLQJ
damage in the cells that leads to premature ageing [47]. Studies in our lab showed that 
ǻncr1 mutant cells exhibit a shortened chronological lifespan (Vilaça et al., unpublished). 
The oxidative stress changes described in almost all NPC models suggest that the 
imbalance in the intracellular redox state may not be restricted to a single cell type, but is 
a general event in NPC phenotype. 
The mechanisms involved in the regulation of mitochondrial function are complex. 
In yeast, cell signalling mediated by the Tor1p and Sch9p protein kinases and by the Sit4p 
protein phosphatase has been shown to play a key role in mitochondrial regulation (see 
Figure 1.7).  
The Tor1p is a serine-threonine protein kinase conserved in all eukaryotes. Tor1p 
resides in a multi-protein complex, TORC1 (sensitive to rapamycin). TORC1 is regulated 
by nutrients more specifically nitrogen source [77]. Sit4p is a serine-threonine Ceramide-
activated protein phosphatase related to type 2A family of protein phosphatases (PP2A) 
that are involved in cell cycle regulation [84,85]. Sch9p is a serine-homologue to 
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mammalian ribosomal S6 kinase (S6K) [88] or Protein Kinase B (PKB/AKT) [89]. Sch9p is 
activated by glucose metabolism [90] and by sphingolipids such as phytosphingosine 
through Pkh1/2p pathway [80]. Down-regulation of these proteins promotes mitochondrial 
function, decreases oxidative stress and increases chronological lifespan [74,75,80]. 
Therefore, we postulated that the deregulation of these proteins could be implicated in the 
mitochondrial dysfunction and increased oxidative stress markers displayed by Ncr1p 
deficient cells. Interestingly, our results suggest that these phenotypes are Sit4p-
dependent. In addition, although Sch9p is activated by Tor1p, SCH9 deletion, in contrast 
with TOR1 deletion, suppressed mitochondrial dysfunction and sensitivity to oxidative 
stress in cells lacking Ncr1p. These results suggest that changes in Sit4p- and Sch9p-
GHSHQGHQWFHOO VLJQDOOLQJ LQǻncr1 mutant cells are Tor1p-independent. Since Sit4p is a 
ceramide-activated protein phosphatase [84] and Sch9p is activated by phytosphingosine 
through Pkh1p/2p [73],  it is likely that changes in these bioactive sphingolipids over-
DFWLYDWH WKHVHSURWHLQVǻncr1 mutant cells. To test this hypothesis, a lipidomic analysis 
should be performed to determine the levels of the different bioactive sphingolipids in 
SDUHQWDODQGǻncr1 cells. In addition, studies to evaluate the activation of the Sit4p and 
Sch9p pathways should be performed. This may be executed through the analysis by 
western-blot of the levels of phosphorylated and active form of these proteins. 
Sphingosine is highly accumulated in all tissues of the body of NPC patients, increasing 4-
fold in brains and 12-fold in livers [11]. In addition, the increase of sphingosine per se can 
promote NPC phenotype in normal cells [11]. Thus, we predict that the increase of 
SK\WRVSKLQJRVLQH LQ ǻncr1 cells may explain the over-activation of Sch9p pathway that 
induces mitochondrial dysfunction. 
The Saccharomyces cerevisiae used as a model for this study is of an extreme 
importance. The simplicity of the organism and the facility to manipulate it makes it easier 
to characterize cellular processes conserved during evolution, such as signalling 
pathways. The fact that Ncr1p, Tor1p, Sit4p and Sch9p have orthologues in mammalians, 
including humans, makes it possible to translate our results to higher organisms.  
 In summary, our results indicate that Ncr1p play an important role in oxidative 
stress resistance. Deletion of SCH9 or SIT4 suppresses mitochondrial dysfunction, 
decreasing intracellular oxidation and the sensitivity to H2O2 RIǻncr1 mutant cells. The 
mechanism underlying this reversion of phenotype is still unclear and has to be 
characterized. Future studies are required to assess if the signalling pathways identified in 
yeast are also affected in more complex models such as fibroblasts from NPC patients, 
and if the pharmacological manipulation of these pathways minimizes or delays the 
progression of NPC disease. 
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